[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-or-metastatic-nsclc-patients-with-classical-egfr-mutations-accompanied-by-met-amplification-or-overexpression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-or-metastatic-nsclc-patients-with-classical-egfr-mutations-accompanied-by-met-amplification-or-overexpression":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100585930","phase-2-glumetinib-combined-with-osimertinib-treatment-for-non-small-cell-lung-cancer-patients-100585930",false,"NCT06908772","Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","A Multicenter Phase II\u002FIII Clinical Study on the Efficacy and Safety of Glumetinib Combined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","Inclusion Criteria:\n\n* 1\\. Able to understand and voluntarily sign the written informed consent form (ICF); 2. Male or female subjects aged 18 to 75 years (inclusive). 3. Patients with NSCLC who have unresectable locally advanced or metastatic disease; 4. At least one measurable lesion, as defined by RECIST 1.1 criteria; 5. ECOG performance status of 0 or 1; 6. Expected survival ≥ 3 months; 7. Adequate function of major organs and bone marrow; 8. Women or man of childbearing potential must use highly effective contraception.\n\nExclusion Criteria:\n\n1. Prior treatment with an EGFR inhibitor or MET inhibitor;\n2. Patients with metastases to meninges; with spinal cord compression; symptomatic and unstable brain metastasis;\n3. Patients who have taken strong inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of the study drug, or who cannot discontinue the use of strong CYP3A4 inducers and inhibitors during the study;\n4. Patients with a history of autoimmune diseases, a history of immunodeficiency, including positive for HIV, or other acquired or congenital immunodeficiency diseases, or a history of organ transplant;\n5. Presence of active infection (e.g., subjects are receiving anti-infection therapy);\n6. Severe or uncontrolled cardiovascular disorder requiring treatment;\n7. Refractory nausea, vomiting, chronic gastrointestinal disease, inability to swallow drugs orally;\n8. Women who are pregnant or breastfeeding;","ALL","18 Years","75 Years",{"count":20,"type":21},390,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.",[28],"Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","NOT_YET_RECRUITING","2025-03-27",{"date":32,"type":33},"2025-04-03","ACTUAL",{"date":35,"type":21},"2025-04-01",{"date":37,"type":21},"2030-01-31",{"name":39,"class":40},"Shanghai JMT-Bio Inc.","INDUSTRY"]